$1.56
0.32% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US8693671021
Symbol
STRO
Sector
Industry

Sutro Biopharma, Inc. Stock price

$1.55
-0.44 22.11% 1M
-3.24 67.64% 6M
-0.29 15.76% YTD
-3.71 70.53% 1Y
-7.37 82.62% 3Y
-7.68 83.21% 5Y
-13.65 89.80% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.06 3.73%
ISIN
US8693671021
Symbol
STRO
Sector
Industry

Key metrics

Market capitalization $127.81m
Enterprise Value $-63.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.58
EV/Sales (TTM) EV/Sales -0.40
P/S ratio (TTM) P/S ratio 0.79
P/B ratio (TTM) P/B ratio 1.15
Revenue growth (TTM) Revenue growth 230.90%
Revenue (TTM) Revenue $160.96m
EBIT (operating result TTM) EBIT $-130.04m
Free Cash Flow (TTM) Free Cash Flow $-109.20m
Cash position $388.25m
EPS (TTM) EPS $-1.62
P/E forward negative
P/S forward 2.16
EV/Sales forward negative
Short interest 4.98%
Show more

Is Sutro Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Sutro Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Sutro Biopharma, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Sutro Biopharma, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Sutro Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
161 161
231% 231%
100%
- Direct Costs 7.08 7.08
17% 17%
4%
154 154
284% 284%
96%
- Selling and Administrative Expenses 42 42
3% 3%
26%
- Research and Development Expense 235 235
38% 38%
146%
-123 -123
29% 29%
-76%
- Depreciation and Amortization 7.08 7.08
17% 17%
4%
EBIT (Operating Income) EBIT -130 -130
28% 28%
-81%
Net Profit -124 -124
28% 28%
-77%

In millions USD.

Don't miss a Thing! We will send you all news about Sutro Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sutro Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15...
Neutral
Seeking Alpha
about 2 months ago
STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but furthe...
Neutral
GlobeNewsWire
4 months ago
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -
More Sutro Biopharma, Inc. News

Company Profile

Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. It focuses on next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Head office United States
CEO William Newell
Employees 302
Founded 2003
Website www.sutrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today